TP53 and breast cancer: reported genetic insights into the biology of breast cancer and summarized that the most common clinically actionable genetic alterations identified using F1CDx in a cohort of 223 advanced breast cancers were TP53 (53.8%), PIK3CA (35%), MYC (22%) CCND1 (19.7%) and FGF19 (19.7%) (13).